<DOC>
	<DOCNO>NCT03062839</DOCNO>
	<brief_summary>This study aim evaluate effect melatonin supplementation adjuvant treatment ADHD adult .</brief_summary>
	<brief_title>Melatonin Adjuvant Treatment ADHD Adults</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Male female age 1860 inclusive . Primary diagnosis ADHD AISRS total score ≥ 24 CGIS ≥4 ( moderately ill bad ) . Understands able , willing , likely fully comply study procedure restriction . Has give write informed consent participate study . BMI le than18.5 great 35 . Any underlying/ history current diagnosis systemic and/or metabolic disease ( e.g . diabetes , Crohn 's disease ) and/or neurological condition state may render subject illegible participate study assess medical history , physical exam , clinical lab evaluation . History uncontrolled hypertension rest systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg ( Subjects well control hypertension stable dose ( 2 month ) antihypertensives allow participate ) . Major depression anxiety disorder focus treatment require take medication . A lifetime history psychosis bipolar disorder Has concurrent chronic unstable medical condition could confound result safety assessment , increase risk subject lead difficulty comply protocol . Subjects take medication CNS effect Subjects history two prior fail adequate trial ADHD treatment due adverse event . Use dietary supplement potential CNS effect , include omega3 supplement , 30 day study initiation throughout study . Clinical history cognitive impairment judgment investigator . Pregnant breastfeeding subject . Women childbearing potential must negative pregnancy test perform screen visit prior randomization . Women childbearing potential must agree use adequate birth control entire duration study . Subjects current ( within last 3 month ) DSMV diagnosis alcohol drug abuse dependence ( exclude nicotine ) . Has take investigational drug take part clinical trial within 30 day prior screen . Any reason , opinion investigator , prevents subject participate study compromise subject safety . Previous use melatonin melatonin analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>